Big Phar­ma vet teams with for­mer Doud­na pupil to launch new epigenome start­up

A for­mer doc­tor­al can­di­date in CRISPR pi­o­neer Jen­nifer Doud­na’s lab found­ed a new biotech seek­ing to wade in­to “epi­ge­net­ics-lev­el gene edit­ing,” and has now se­cured enough cap­i­tal to do just that.

The new San Fran­cis­co start­up, Epic Bio, put out word ear­ly Tues­day that it had of­fi­cial­ly launched, se­cur­ing a Se­ries A worth $55 mil­lion. That should be enough to fund the biotech’s dash to­wards the clin­ic, and CEO Am­ber Salz­man tells End­points News the goal is to reach it by the end of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER